Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01999361 · ClinicalTrials.gov registry record · NA

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

A NA study of Type 1 Diabetes Mellitus, sponsored by Rodolfo Alejandro.

Recruiting
Registry status
NA
Development phase
18
Enrollment target
1
Study location

NCT01999361 is a NA study of Type 1 Diabetes Mellitus that is actively recruiting participants, run by Rodolfo Alejandro. The registered enrollment target is 18 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01999361, a NA study of Type 1 Diabetes Mellitus, is actively recruiting participants, sponsored by Rodolfo Alejandro.

RECRUITING
Registry status
NA
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

Conditions Studied

Interventions

  • DRUG Myfortic

Study Locations (1)

Florida

  • Diabetes Research Institute - Miami

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2009-01
Est. Completion 2028-12
Phase NA

Sponsor

Rodolfo Alejandro

10 total trials

What the Registry Record Tells You About NCT01999361

The ClinicalTrials.gov registry entry for NCT01999361 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (87% lower). The listed sponsor is Rodolfo Alejandro, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Myfortic is the first listed.

NCT01999361 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01999361 about?

NCT01999361 is a clinical study titled "Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss". This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

What is the current status of trial NCT01999361?

This trial is currently recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2009-01. Estimated completion is 2028-12.

What conditions does trial NCT01999361 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT01999361?

The interventions under investigation include: Myfortic (DRUG).

Who is sponsoring clinical trial NCT01999361?

This trial is sponsored by Rodolfo Alejandro, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01999361 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.